Table 1 The Baseline Demographic Characteristics and Outcome of the Development and Validation Set
From: Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis
Variables | Subgroups | Development set (n = 96) No. of patients (%) Median (range) | Temporal validation set (n = 24) No. of patients (%) Median (range) | P value |
|---|---|---|---|---|
Outcome | Non MSE | 26 (27.1) | 4 (16.7) | 0.292 |
MSE | 70 (72.9) | 20 (83.3) | ||
Gender | Male | 46 (47.9) | 15 (62.5) | 0.201 |
Female | 50 (52.1) | 9 (37.5) | ||
Age at onset | EOMG | 62 (64.6) | 16 (66.7) | 0.815 |
LOMG | 25 (26.0) | 5 (20.8) | ||
Elderly-onset MG | 9 (9.6) | 3 (12.5) | ||
MGFA classification | II | 62 (64.6) | 16 (66.7) | 0.999 |
III | 29 (30.2) | 7 (29.2) | ||
IV | 5 (5.2) | 1 (4.2) | ||
Thymoma | No | 62 (66.0) | 19 (79.2) | 0.213 |
Yes | 32 (34.0) | 5 (20.8) | 0.633 | |
Thymectomy | No | 70 (74.5) | 19 (79.2) | |
Yes | 24 (25.5) | 5 (20.8) | ||
Worsening | No | 24 (25.0) | 9 (37.5) | 0.22 |
Yes | 72 (75.0) | 15 (62.5) | ||
Autoimmune disease | No | 86 (89.6) | 20 (83.3) | 0.619 |
Yes | 10 (10.4) | 4 (16.7) | ||
Disease duration, months | 7 (3.0–30.5) | 4 (2.0–14.5) | 0.305 | |
Anti-AChR Abs titer, nmol/L | 6 (2.6–10.3) | 8 (2.6–12.4) | 0.316 | |
Pyridostigmine dosage, mg/day | 180 (90.0–180.0) | 180 (180.0–180.0) | 0.557 | |
MMT score | 14 (7.0–19.0) | 14 (7.3–19.8) | 0.743 | |
MG-ADL score | 5 (4.0–8.0) | 5 (4.0–7.0) | 0.377 | |
Bulbar score | 2 (1.0–3.0) | 1 (0–2.8) | 0.145 | |
Respiratory score | 0 (0–1.0) | 0 (0–0) | 0.035* | |
Limb score | 1 (0–2.0) | 0 (0–1.0) | 0.103 | |
Ocular score | 3 (1.0–4.0) | 3 (2.0–4.0) | 0.182 | |
QMG score | 11 (9.0–14.0) | 12 (7.0–16.0) | 0.638 | |
Extraocular muscle score | 3 (1.0–4.0) | 4 (2.0–5.0) | 0.038 | |
Bulbar muscle score | 0 (0–1.0) | 1 (0–2.0) | 0.110 | |
Respiratory muscle score | 0 (0–1.0) | 0 (0–0) | 0.002* | |
Gross motor score | 6 (4.0–8.0) | 6 (2.5–8.0) | 0.220 | |
Axial motor score | 1 (1.0–2.0) | 1 (1.0–2.0) | 0.869 | |